What question did this study set out to answer?

To evaluate the feasibility of treatment tapering options in rheumatoid arthritis patients in remission or low disease activity.

March 3, 2026Open Access

Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)

Puntos clave

To evaluate the feasibility of treatment tapering options in rheumatoid arthritis patients in remission or low disease activity.
Conducted a randomised, controlled trial
Compared extending TNF inhibitor intervals to dose reduction of methotrexate
Included patients with rheumatoid arthritis in remission or low disease activity
Treatment tapering may not be feasible for all patients with low disease activity
Extending TNF inhibitor intervals and reducing methotrexate dose are reasonable options for some patients
Implications for managing rheumatoid arthritis effectively without fatigue from aggressive treatment

Resumen

Treatment tapering may not be feasible in patients with low disease activity, whereas both extending the TNF inhibitor interval and reducing the methotrexate dose may be reasonable options for patients in remission.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Imai et al. (Sun,) studied this question.

synapsesocial.com/papers/69a67e0ef353c071a6f09f29 https://doi.org/https://doi.org/10.1016/j.ard.2026.02.004

Me gusta

Guardar

Ver artículo completo